<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769506</url>
  </required_header>
  <id_info>
    <org_study_id>ASP-1929-301</org_study_id>
    <nct_id>NCT03769506</nct_id>
  </id_info>
  <brief_title>ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy</brief_title>
  <official_title>A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rakuten Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rakuten Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's&#xD;
      Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous&#xD;
      Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of&#xD;
      Therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have an Experimental Arm and a Control Arm.&#xD;
&#xD;
      Experimental Arm:&#xD;
&#xD;
      Patients may receive repeated ASP-1929 PIT interventions for a period of up to 12 months&#xD;
      after randomization until the patient has complete remission, progressive disease that is no&#xD;
      longer amendable to study treatment, patient experiences intolerable side effects, or patient&#xD;
      discontinues study treatment.&#xD;
&#xD;
      Control Arm:&#xD;
&#xD;
      Patients may be treated with physician's choice SOC until the patient has progressive&#xD;
      disease, patient experiences intolerable side effects, or patient discontinues study&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time to progression of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of survival between the two treatment arms</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>ASP-1929 Photoimmunotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of ASP1929 PIT therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physician's Choice SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel, cetuximab, methotrexate, paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ASP-1929 Photoimmunotherapy</intervention_name>
    <description>Use of ASP-1929 PIT therapy</description>
    <arm_group_label>ASP-1929 Photoimmunotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's Choice SOC</intervention_name>
    <description>docetaxel, cetuximab, methotrexate, or paclitaxel</description>
    <arm_group_label>Physician's Choice SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Overall Inclusion Criteria:&#xD;
&#xD;
          -  Have a histologically confirmed locoregional persistent, recurrent or second primary&#xD;
             squamous cell carcinoma of the head and neck, not amenable to curative treatment&#xD;
&#xD;
          -  Have failed or progressed on or after at least 2 lines of therapy for squamous cell&#xD;
             carcinoma of the head and neck, one of which must be prior systemic platinum-based&#xD;
             chemotherapy&#xD;
&#xD;
          -  Have completed prior curative radiation therapy for treatment of their head and neck&#xD;
             region&#xD;
&#xD;
          -  Have locoregional head and neck tumor site(s) that are all accessible to illumination&#xD;
&#xD;
          -  Have target tumors that are clearly measurable by contract enhanced CT scan&#xD;
&#xD;
          -  Have a life expectancy of &gt; 6 months, based on Investigator judgment&#xD;
&#xD;
          -  Male participants must agree to use contraception during the treatment period and for&#xD;
             at least 6 months after the last ASP-1929 infusion&#xD;
&#xD;
          -  Female patients of childbearing potential must not be pregnant or breastfeeding and&#xD;
             agrees to follow the contraceptive guidance during the treatment period and for at&#xD;
             least 6 months after the last dose of trial intervention and must refrain from&#xD;
             breastfeeding for at least 2 months after the last ASP-1929 infusion&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1&#xD;
&#xD;
        Overall Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of significant (&gt; Grade 3) cetuximab infusion reactions&#xD;
&#xD;
          -  Have been treated with prior systematic chemotherapy or targeted small molecule&#xD;
             therapy or radiation therapy within 2 weeks of trial Day 1 or not recovered from&#xD;
             adverse events due to a previously administered agent&#xD;
&#xD;
          -  Have been treated with an anticancer monoclonal antibody therapy within 4 of trial Day&#xD;
             1 or have not recovered from adverse events due to previously administered agent&#xD;
&#xD;
          -  Have been treated with an investigational agent or intervention within 4 weeks of&#xD;
             trial Day 1 or have not recovered from adverse events, due to previously administered&#xD;
             agent or intervention&#xD;
&#xD;
          -  Have a present history of distant metastatic disease (M1)&#xD;
&#xD;
          -  Have an active undergoing treatment or have a diagnosis of an active cancer other than&#xD;
             nonmelanoma skin cancer or HNSCC&#xD;
&#xD;
          -  Have a tumor in enhanced CT or MRI scan invading a major blood vessel, unless the&#xD;
             vessel has been embolized, stented or surgically ligated to prevent potential bleeding&#xD;
             from a blood vessel&#xD;
&#xD;
          -  Have impaired hepatic function&#xD;
&#xD;
          -  Have impaired renal function&#xD;
&#xD;
          -  Have uncontrolled intercurrent illness including, but not limited to, ongoing or&#xD;
             active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situations that would limit&#xD;
             compliance with trial requirements&#xD;
&#xD;
          -  Have been previously treated or randomized to any trial using ASP-1929 or RM-1929 PIT&#xD;
             as the study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Arron, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rakuten Medical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sumera Raoof, MD, MPH</last_name>
    <phone>+1 858-925-5619</phone>
    <email>clinicaltrialinfo@rakuten-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzel Rodriguez</last_name>
    </contact>
    <investigator>
      <last_name>Francisco Jose Civantos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estefani Gonzalez</last_name>
    </contact>
    <investigator>
      <last_name>Mary Jo Fidler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitney Michels</last_name>
    </contact>
    <investigator>
      <last_name>Joseph Valentino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Gaggin</last_name>
    </contact>
    <investigator>
      <last_name>Steven Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute, Part of Allina Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brittany Pulkrabek</last_name>
    </contact>
    <investigator>
      <last_name>Samir Khariwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Head &amp; Neck Institute - Center for Head and Neck Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Usuriello</last_name>
    </contact>
    <investigator>
      <last_name>Dennis Kraus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Morris</last_name>
    </contact>
    <investigator>
      <last_name>Bryan Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University - Sidney Kimmel Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Poller</last_name>
    </contact>
    <investigator>
      <last_name>David Cognetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Paul</last_name>
    </contact>
    <investigator>
      <last_name>Karthik Rajasekaran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Young</last_name>
    </contact>
    <investigator>
      <last_name>Kyle Mannion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanda Grant</last_name>
    </contact>
    <investigator>
      <last_name>Baran Sumer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Reeves</last_name>
    </contact>
    <investigator>
      <last_name>Ann Gillenwater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olusegun Adelaja</last_name>
    </contact>
    <investigator>
      <last_name>Kaur Varinder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Office of Anthanassios Argiris, MD</name>
      <address>
        <city>Maroussi</city>
        <state>Athens</state>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akihiro Homma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Kiyota</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center</name>
      <address>
        <city>Natori-shi</city>
        <state>Miyagi</state>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Department of Otorhinolaryngology</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seiichi Yoshimoto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>HM University Sanchinarro Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Niaosong</city>
        <state>Kaohsiung</state>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Yen Chien</last_name>
    </contact>
    <investigator>
      <last_name>Chih-Yen Chien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Zhongzheng</city>
        <state>Taipei</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pei-Jen Lou</last_name>
    </contact>
    <investigator>
      <last_name>Pei-Jen Lou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Medical Foundation</name>
      <address>
        <city>Changhua</city>
        <zip>50004</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mu-Kuan Chen</last_name>
    </contact>
    <investigator>
      <last_name>Mu-Kuan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Hung Hua</last_name>
    </contact>
    <investigator>
      <last_name>Chun-Hung Hua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen-Chi Wang</last_name>
    </contact>
    <investigator>
      <last_name>Chen-Chi Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muh-Hwa Yang</last_name>
    </contact>
    <investigator>
      <last_name>Muh-Hwa Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai-Ping Chang</last_name>
    </contact>
    <investigator>
      <last_name>Kai-Ping Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Greece</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int Immunol. 2021 Jan 1;33(1):7-15. doi: 10.1093/intimm/dxaa037.</citation>
    <PMID>32496557</PMID>
  </results_reference>
  <results_reference>
    <citation>Kobayashi H, Choyke PL. Near-Infrared Photoimmunotherapy of Cancer. Acc Chem Res. 2019 Aug 20;52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. Epub 2019 Jul 23. Review.</citation>
    <PMID>31335117</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rakuten Medical</keyword>
  <keyword>ASP-1929</keyword>
  <keyword>PIT</keyword>
  <keyword>Photoimmunotherapy</keyword>
  <keyword>HNC</keyword>
  <keyword>HNSCC</keyword>
  <keyword>Head and neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

